Literature DB >> 15295875

Determination of trimetazidine dihydrochloride in the presence of its acid-induced degradation products.

Lories I Bebawy1, Mohammed F El Tarras, Samah A El Sabour.   

Abstract

Three methods are presented for the determination of trimetazidine dihydrochloride in the presence of its acid-induced degradation products. The first method was based on measurement of first-derivative D1 value of trimetazidine dihydrochloride at 282 nm over a concentration range of 8.00-56.00 microg/mL with mean percentage accuracy of 99.80+/-1.17. The second method was based on first derivative of the ratio spectra DD1 at 282 nm over the same concentration range with the percentage accuracy of 99.14+/-0.68. The third method was based on separation of trimetazidine dihydrochloride from its acid-induced degradation products followed by densitometric measurement of the spots at 215 nm. The separation was performed on silica gel 60 F254 using methanol-ammonia (100+/-1.5, v/v) as mobile phase. This method was applicable for determination of the intact drug in the presence of its degradation products over a concentration range of 2.00-9.00 microg/spot with mean percentage accuracy of 99.86+/-0.92. The proposed methods were successfully applied for the determination of trimetazidine dihydrochloride in bulk powder, laboratory-prepared mixtures containing different percentages of degradation products, and pharmaceutical dosage forms. The validity of results was assessed by applying the standard addition technique. The results obtained agreed statistically with those obtained by the reported method.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295875

Source DB:  PubMed          Journal:  J AOAC Int        ISSN: 1060-3271            Impact factor:   1.913


  1 in total

1.  Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization.

Authors:  Noha N Atia; Hesham M Tawfeek; Azza H Rageh; Marwa R El-Zahry; Ahmed Abdelfattah; Mahmoud A Younis
Journal:  Saudi Pharm J       Date:  2019-02-05       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.